Proglumetacin, an orally active and potent cyclo-oxygenase inhibitor, inhibits the SARS-CoV Mpro (main protease of the SARS-CoV-2) with an AC50 of 8.9 μM, indicating its potential efficacy against SARS-CoV-2. It exhibits anti-inflammatory activity, making it suitable for research into conditions like Rheumatoid arthritis and Allergic air pouch inflammation[1][2][3].